Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Lessons from the withdrawal of rofecoxib.

Dieppe PA, Ebrahim S, Martin RM, Jüni P.

BMJ. 2004 Oct 16;329(7471):867-8. No abstract available.

2.

Lessons on prescribing and drug safety from the withdrawal of rofecoxib.

Nelson M, Cicuttini F.

Aust Fam Physician. 2004 Dec;33(12):965-6. No abstract available.

3.

Ten lessons to be learned from the withdrawal of Vioxx (rofecoxib).

Carné X, Cruz N.

Eur J Epidemiol. 2005;20(2):127-9. No abstract available.

PMID:
15792277
4.

The Vioxx debacle.

Alpert JS.

Am J Med. 2005 Mar;118(3):203-4. No abstract available.

PMID:
15745713
5.

The Vioxx debacle revisited.

Mohapatra PR, Janmeja AK.

Am J Med. 2005 Sep;118(9):1058. No abstract available.

PMID:
16164909
6.

Lessons from the withdrawal of rofecoxib: Observational studies should not be forgotten.

Oakley G Jr.

BMJ. 2004 Dec 4;329(7478):1342. No abstract available.

7.

Tolerability of rofecoxib.

Asero R.

Allergy. 2001 Sep;56(9):916-7. No abstract available.

8.

Probable rofecoxib-induced thrombocytopenia.

Kentos A, Robin V, Lambermont M, Jurdan M, Pignarelli M, Feremans W.

Rheumatology (Oxford). 2003 May;42(5):699-700. No abstract available.

PMID:
12709555
9.

Tolerability of rofecoxib versus naproxen.

Hanauer LB.

Ann Intern Med. 2004 Jun 15;140(12):1059; author reply 1060. No abstract available.

PMID:
15197026
10.

Rofecoxib-induced pseudoporphyria.

Markus R, Reddick ME, Rubenstein MC.

J Am Acad Dermatol. 2004 Apr;50(4):647-8. No abstract available.

PMID:
15034522
11.
12.

Adverse oral reactions associated with the COX-2 inhibitor rofecoxib.

Bagán JV, Thongprasom K, Scully C.

Oral Dis. 2004 Nov;10(6):401-3.

PMID:
15533219
13.

Tolerability of rofecoxib versus naproxen.

Rusche JM.

Ann Intern Med. 2004 Jun 15;140(12):1059; author reply 1060. No abstract available.

PMID:
15197028
14.

Tolerability of rofecoxib versus naproxen.

Jenkinson ML.

Ann Intern Med. 2004 Jun 15;140(12):1059-60; author reply 1060. No abstract available.

PMID:
15197027
15.

Discontinuation of Vioxx.

Garattini S, Bertelé V.

Lancet. 2005 Jan 1-7;365(9453):24. No abstract available.

PMID:
15639671
16.

[Rofecoxib and gynecomastia: the first case].

Schmutz JL, Barbaud A, Trechot P.

Ann Dermatol Venereol. 2004 Aug-Sep;131(8-9):856. French. No abstract available.

PMID:
15505566
17.

Intracranial hypertension induced by rofecoxib.

Jacob S, Rajabally YA.

Headache. 2005 Jan;45(1):75-6.

PMID:
15663617
18.

New use approved for Vioxx.

[No authors listed]

FDA Consum. 2002 Jul-Aug;36(4):3. No abstract available.

19.

[Wrong information concerning rofecoxib].

Rygnestad T, Slørdal L.

Tidsskr Nor Laegeforen. 2002 Aug 30;122(20):2035. Norwegian. No abstract available.

20.

Severe cholestasis and acute renal failure related to rofecoxib.

Linares P, Vivas S, Jorquera F, Olcoz JL, de Leon B, Oritz de Urbina J.

Am J Gastroenterol. 2004 Aug;99(8):1622-3. No abstract available.

PMID:
15307886

Supplemental Content

Support Center